|
Recombinant Human C7 (Complement Component 7) |
||||||
|
|
|
Cat.No.: |
REH-P10643 |
|
|
|
|
Product Background |
||||||
|
Human Complement Component 7 |
||||||
|
Complement component 7 is a component of the complement system. It belongs to the complement C6/C7/C8/C9 family. It contains 1 EGF-like domain, 1 LDL-receptor class A domain, 1 MACPF domain, 2 Sushi (CCP/SCR) domains and 2 TSP type-1 domains. Complement component 7 serves as a membrane anchor. It participates in the formation of Membrane Attack Complex (MAC). People with C7 deficiency are prone to bacterial infection. It is a constituent of MAC that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. Defects in C7 are a cause of complement component 7 deficiency (C7D). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. |
||||||
|
Product Information |
||||||
|
Source |
Escherichia coli. |
|||||
|
Molecular Weight |
Approximately 43.1 kDa, Ser122~His456 with N-terminal His Tag. |
|||||
|
AA Sequence |
SERRPSCDI DKPPPNIELT GNGYNELTGQ FRNRVINTKS FGGOCRKVFS GDGKDFYRLS GNVLSYTFQV KINNDFNYEFYNSTWSYVKHTSTEHTSSSR KRSFFRSSSS SSRSYTSHTN EIHKGKSYQL LVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSLYDYS AYRRLIDOYG THYLQSGSLG GEYRVLFYVD SEKLKQNDFN SVEEKKCKSSGWHFVVKFSS HGCKELENALKAASGTONNV LRGEPFIRGG GAGFISGLSY LELDNPAGNK RRYSAWAESV TNLPQVIKQKLTPLYELVKE VPCASVKKLYLKWALEEYLD EFDPCH |
|||||
|
Biological Activity |
Positive Control; Immunogen; SDS-PAGE; WB |
|||||
|
Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
|||||
|
Formulation |
Lyophilized from a 0.2 mm filtered concentrated solution in PBS, pH 7.4. |
|||||
|
Endotoxin |
Less than 1 EU/mg of this product as determined by LAL method. |
|||||
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ¡Ü -20 ¡ãC. Further dilutions should be made in appropriate buffered solutions. |
|||||
|
Purity |
> 90 % by SDS-PAGE and HPLC analyses. |
|||||
|
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|||||
|
12 months from date of receipt, -20 to -70 ¡ãC as supplied. |
||||||
|
1 month, 2 to 8 ¡ãC under sterile conditions after reconstitution. |
||||||
|
3 months, -20 to -70 ¡ãC under sterile conditions after reconstitution. |
||||||
|
Usage Information |
||||||
|
This product is offered by BioCytoSci only for Scientific Research & Laboratory USE. NOT FOR OTHER USE. |
||||||
|
Order Information |
|
|
|
|
|
|
|
Cata.No. |
Quantity |
Price($) |
Price($) |
Price(£¤) |
||
|
REH-P10643 |
10ug |
$125.00 |
€137.50 |
£¤1,250.00 |
||
|
REH-P10643 |
50ug |
$350.00 |
€385.00 |
£¤3,500.00 |
||
|
REH-P10643 |
1mg |
$4,200.00 |
€4,620.00 |
£¤42,000.00 |
||
|
Free Delivery on orders over $200.00. |
||||||
|
We Devoted Ourselves To The Development Of Biomedical Research Reagent. |
||||||
